<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The escalating epidemic of <z:hpo ids='HP_0001513'>obesity</z:hpo> has driven the prevalence of both type 1 and 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> to historically high levels </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> low-grade <z:mp ids='MP_0001845'>inflammation</z:mp>, which is present in both type 1 and type 2 diabetics, contributes to the pathogenesis of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The accumulation of activated innate immune cells in metabolic tissues results in release of <z:mp ids='MP_0002501'>inflammatory mediators</z:mp>, in particular, IL-1β and TNFα, which promote systemic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and β-cell damage </plain></SENT>
<SENT sid="3" pm="."><plain>In this article, we discuss the central role of innate immunity and, in particular, the macrophage in insulin sensitivity and resistance, β-cell damage, and autoimmune <z:mp ids='MP_0004031'>insulitis</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>We conclude with a discussion of the therapeutic implications of this integrated understanding of diabetic pathology </plain></SENT>
</text></document>